A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study by James S. McCarthy et al.
McCarthy et al. Malar J  (2016) 15:469 
DOI 10.1186/s12936-016-1511-3
RESEARCH
A Phase II pilot trial to evaluate  
safety and efficacy of ferroquine against early 
Plasmodium falciparum in an induced 
blood-stage malaria infection study
James S. McCarthy1,2, Thomas Rückle3, Elhadj Djeriou4, Cathy Cantalloube8, Daniel Ter‑Minassian4, 
Mark Baker3,7, Peter O’Rourke1, Paul Griffin1,2,5,6, Louise Marquart1, Rob Hooft van Huijsduijnen3 
and Jörg J. Möhrle3*
Abstract 
Background: Ferroquine (SSR97193) is a candidate anti‑malarial currently undergoing clinical trials for malaria. To 
better understand its pharmacokinetic (PK) and pharmacodynamic (PD) parameters the compound was tested in the 
experimentally induced blood stage malaria infection model in volunteers.
Methods: Male and non‑pregnant female aged 18–50 years were screened for this phase II, controlled, single‑centre 
clinical trial. Subjects were inoculated with ~1800 viable Plasmodium falciparum 3D7A‑infected human erythrocytes, 
and treated with a single‑dose of 800 mg ferroquine. Blood samples were taken at defined time‑points to measure 
PK and PD parameters. The blood concentration of ferroquine and its active metabolite, SSR97213, were measured on 
dry blood spot samples by ultra‑performance liquid chromatography with tandem mass spectrometry (LC‑MS/MS). 
Parasitaemia and emergence of gametocytes were monitored by quantitative PCR. Safety was determined by record‑
ing adverse events and monitoring clinical laboratory assessments during the course of the study.
Results: Eight subjects were enrolled into the study, inoculated with infected erythrocytes and treated with 800 mg 
ferroquine. Ferroquine was rapidly absorbed with maximal exposure after 4–8 and 4–12 h exposure for SSR97213. 
Non‑compartmental PK analysis resulted in estimates for half‑lives of 10.9 and 23.8 days for ferroquine and SSR97213, 
respectively. Parasite clearance as reported by parasite reduction ratio was 162.9 (95 % CI 141–188) corresponding to 
a parasite clearance half‑life of 6.5 h (95 % CI: 6.4–6.7 h). PK/PD modelling resulted in a predicted minimal parasiticidal 
concentration of 20 ng/mL, and the single dosing tested in this study was predicted to maintain an exposure above 
this threshold for 454 h (37.8 days). Although ferroquine was overall well tolerated, transient elevated transaminase 
levels were observed in three subjects. Paracetamol was the only concomitant treatment among the two out of these 
three subjects that may have played a role in the elevated transaminases levels. No clinically significant ECG abnor‑
malities were observed.
Conclusions: The parameters and PK/PD model derived from this study pave the way to the further rational develop‑
ment of ferroquine as an anti‑malarial partner drug. The safety of ferroquine has to be further explored in controlled 
human trials.
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Background
Despite medical progress, malaria still ranks among the 
deadliest infectious diseases, causing nearly half a mil-
lion deaths among the estimated 214 million cases in 
2015 [1]. Malaria is a World Health Organization (WHO) 
global development priority, and the WHO has shifted its 
focus from disease control to elimination. Lessons from 
the past have taught us that progress towards this goal 
entails both the judicious stewardship of existing treat-
ments and a steady stream of new drugs [2–5]. Plasmo-
dium parasite resistance against earlier anti-malarials, 
chloroquine, amodiaquine and sulfadoxine/pyrimeth-
amine, is now widespread. Artemisinins, the most potent 
and rapidly-acting anti-malarial agents available today 
[6], are associated with high recrudescence rates when 
used as monotherapy, and must be used in combination 
with other drugs. Worryingly, artemisinin resistance is 
now seen in the Greater Mekong Subregion [7–10]. Thus, 
new drugs with new mechanisms of action are urgently 
needed. Over recent years a number of new, exciting 
anti-malarial candidates have emerged [4]. The challenge 
is to prioritize these for further clinical development and 
to define their pharmacokinetic (PK) and pharmacody-
namic (PD) properties in detail, allowing decisions on 
optimal dosing and the rational choice of partner drugs 
in a cost-effective and timely procedure.
The experimentally induced blood stage malaria 
(IBSM) infection model [11] has facilitated the devel-
opment of new treatments for malaria. In this model, 
volunteers are inoculated with Plasmodium falciparum-
infected red blood cells. The model allows measuring 
critical PK and PD parameters as well as drug safety 
information in a controlled clinical setting, with para-
sitaemia that is orders of magnitude below those asso-
ciated with severe malaria symptoms. The model has 
already been used with well-established anti-malarials 
(piperaquine [12, 13] and mefloquine [14]) and experi-
mental drugs (unpublished observations, McCarthy et al. 
[12]) allowing for benchmarking and uniform PK/PD 
modelling, accelerating dose finding and synergistic drug 
partner selection.
Ferroquine (SSR97193, ferrochloroquine) is a drug in 
development derived from the 4-aminoquinoline chlo-
roquine. Its structure consists of a chloroquine backbone 
conjugated with ferrocene [15–18]. In vitro studies have 
shown that the drug has the potential to overcome para-
site resistance against chloroquine and other drugs [19–
22]. Ferroquine’s main metabolite is N-monodesmethyl 
ferroquine (N-desmethyl-ferroquine, or SSR97213), 
which has similar in vitro activity as ferroquine on chlo-
roquine-sensitive P. falciparum strains [16]. Ferroquine 
has shown good activity against a number of clinical 
Plasmodium isolates [23–25], and in preclinical Plasmo-
dium berghei and Plasmodium vinckei mouse malaria 
models [26, 27]. In a Phase I trial the compound was well 
tolerated at doses up to 1600 mg (single dose) and up to 
800  mg as a repeat dose [28]. Ferroquine was recently 
tested as monotherapy in patients, and combined with 
artesunate, in a Phase II trial conducted in four African 
countries [29, 30]. A 3 days combination treatment with 
doses of 2, 4 and 6 mg/kg/day ferroquine and 4 mg/kg/
day artesunate resulted in 97–99  % cure rates, whereas 
the 4  mg/kg ferroquine monotherapy produced a 79  % 
cure rate.
To further develop ferroquine for the treatment of 
malaria a thorough understanding of the drug’s PK and 
PD properties is necessary. Therefore, a single-dose, 
phase II trial was performed in the human malaria 
model. Healthy volunteers were inoculated with infected 
erythrocytes and treated with a single dose of ferroquine. 
The principal aim of the current study was to establish an 
accurate PK/PD model for ferroquine in the IBSM model, 




This was a single-centre phase II, clinical trial (registra-
tion number ACTRN12613001040752). It was conducted 
between October 17 and December 11, 2013 at Q-Pharm 
Pty Ltd in Australia. The primary objective was to charac-
terize the PK/PD relationship of ferroquine on clearance 
of P. falciparum from the blood in volunteers following 
experimental P. falciparum infection. The secondary objec-
tive was to characterize the PK profile of ferroquine in this 
model, as well as to assess the drug’s safety and tolerabil-
ity. The study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki (1964 and subsequent 
updates), and with the NHMRC National Statement on 
Ethical Conduct in Human Research (2007). The conduct 
of the study was in accordance with the Notes for Guid-
ance on Good Clinical Practice (CPMP/ICH/135/95), as 
adopted by the Australian Therapeutic Goods Administra-
tion (2000). Enrolment included male and non-pregnant 
female volunteers between 18 and 50 years of age, who met 
the inclusion criteria and none of the exclusion criteria.
Keywords: Induced blood‑stage malaria (IBSM), Drug discovery, Ferroquine, Malaria, Plasmodium falciparum, 
Pharmacokinetic/pharmacodynamic modelling, Translational models, SSR97193, Ferrochloroquine
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Study conduct
Treatments
Subjects were inoculated with ~1800 viable P. falciparum 
3D7-infected human erythrocytes administered intra-
venously (single dose) as described previously [11]. The 
day of inoculation was considered as day 0 for every sub-
ject. Subjects were monitored on an outpatient basis for 
adverse events and any unexpected early onset of symp-
toms, signs or parasitological evidence of malaria. Vol-
unteers were treated with ferroquine the morning after 
the parasitaemia measured by quantitative PCR (qPCR) 
first exceeded a threshold of ≥1000 parasites/mL, or ear-
lier if clinical manifestation of malaria appeared. Subjects 
were then confined for 48  h for ferroquine administra-
tion, determination of parasite load and drug levels, 
and safety monitoring. A single dose of 800  mg ferro-
quine was administered to volunteers in a fasting state 
in 100 mg-capsules (Sanofi France SA). If clinically well, 
subjects were then discharged and monitored on an out-
patient basis for safety, ferroquine/SSR97213 blood levels 
and the continued presence of malaria parasites as meas-
ured by qPCR. The effects of ferroquine on parasitae-
mia were observed for up to 16 days before compulsory 
rescue treatment: Rescue treatment on day 16 con-
sisted of artemether/lumefantrine (A/L; Riamet®, 20 mg 
artemether/120  mg lumefantrine; Novartis Pharmaceu-
ticals Australia Pty Ltd.) administered as four tablets 
every 12 h for 60 h. Rescue treatment would be provided 
earlier if recrudescence or clinical failure were observed. 
As a safety measure, parasitaemia continued to be moni-
tored following the A/L therapy and was again assessed 
at the end of study visit, which took place on day 28. If 
gametocytaemia was detected, as determined by quanti-
tative qPCR for the female gametocyte-specific transcript 
pfs25, subjects were treated post-A/L treatment with a 
single 45 mg dose of primaquine, administered in tablets 
each containing 13.2 mg primaquine phosphate (equiva-
lent to 7.5 mg primaquine; Boucher and Muir Pty Ltd).
Measurement of ferroquine/SSR97213 blood 
concentration
Concentrations of ferroquine and SSR97213 were meas-
ured in whole blood. Blood samples were taken pre-dose 
and at 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 144 h post 
ferroquine dosing; then on days 8, 11, 14 and 28 (End 
of the Study). The blood was collected in EDTA tubes, 
then processed and spotted onto dried blood spot (DBS) 
cards. Ferroquine and SSR97213 plasma concentration 
was measured in DBS samples by UPLC column sepa-
ration with reversed-phase chromatography followed 
by detection with triple-stage quadrupole MS/MS in 
the selected reaction monitoring mode. This assay was 
validated in a separate study using [2H6]-ferroquine and 
[2H313C]-SSR97213. In summary, sensitivity for both was 
5–1000  ng/mL for 10  mL injections, with 3.5–5.1 and 
2.6–6.4 % intra-run precision (n = 20, four concentration 
levels), with accuracies of 98.6–104 and 97–102 % for fer-
roquine resp. SSR97213.
Measurement of parasitaemia
Blood samples were taken to quantify parasitaemia by 
qPCR as described [31]. Post inoculum, blood samples 
were taken daily, then twice daily after a positive PCR sig-
nal was obtained. Upon ferroquine administration (after 
reaching the 1000 parasites/mL threshold) samples were 
taken at 0, 2, 4, 8, 12, 16, 20, 24, 30, 36, 48, 60, 72, 84, 96, 
120 and 144 h post ferroquine dosing, then three times 
a week until two consecutive negative PCR values were 
observed. Blood samples were also taken on the morning 
of the first A/L dose and the two subsequent mornings; 
pre- and post any primaquine dose and then at the end of 
study visit. Whole-blood samples were stored on ice. The 
detection limit was 64 parasites/mL. P. falciparum game-
tocytaemia was quantified using a previously described 
RT-PCR assay specific for pfs25, a P. falciparum mRNA 
transcript expressed in mature female gametocytes [13].
Safety assessments
At screening, all subjects underwent a complete physical 
examination, monitoring of vital signs, ECG and routine 
biochemistry and haematology testing. During confine-
ment, vital signs were measured three times per day and 
all symptoms and adverse events were recorded per pro-
tocol (see Additional file 1). Blood samples were assayed 
for a number of haematological abnormalities, including 
total protein, globulin, aspartate transaminase (AST), 
alanine transaminase (ALT), lymphocytes, neutrophils, 
white cell count, platelets, haemoglobin, haematocrit, red 
blood cell count, haemolysis index, ferritin, iron, LDH, 
creatine kinase, sodium, potassium, chloride, albumin, 
urea, total iron binding capacity (TIBC), cholesterol and 
HDL ratio, triglyceride, bilirubin, bicarbonate and alka-
line phosphatase.
Study outcomes
The outcomes of this study were the PK parameters Cmax, 
Tmax, t½, AUCt and AUCinf of ferroquine and SSR97213; 
PD parameters, including parasite reduction profile and 
parasite reduction ratio (PRR); safety monitoring, includ-
ing 12-lead electrocardiograms (ECG; see Additional 
file 1).
Sample size
Historically, a number of eight subjects in a dose cohort 
has proven sufficient to characterize the effects of a 
drug on malaria parasite kinetics following induction in 
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healthy volunteers using inoculation with blood stage P. 
falciparum [11, 12]. In this study, one cohort (n = 8) was 
recruited.
PK, PD and PK/PD modelling
Non-compartmental PK analysis was performed using 
WinNonin (Pharsight, Cary, US). The area under the 
curve was determined using log-linear integration up 
to last time point measure (AUCt) and extrapolated to 
infinity (AUCinf). The gradient of the elimination phase, 
λz, was determined by log-linear regression leading to 
calculation of the elimination half-life. The maximal con-
centration following ferroquine administration (Cmax) 
and the time it was reached (Tmax) were reported. All 
parameters were summarized using appropriate statistics 
including geometric mean or median. Compartmental 
modelling was performed using NONMEM ([32]; version 
6 or higher).
For PD analysis, each subject’s Parasite Reduction Ratio 
(PRR; 48  h) and parasite clearance half life and corre-
sponding 95 % confidence intervals (CI) were calculated 
using the slope and corresponding standard error (SE) of 
the optimal regression model [33]. The weighted average 
slope estimate and corresponding SE were calculated by 
the inverse-variance method. Where the model fit was 
adequate (p < 0.001), subjects’ data were used to estimate 
the PRR for each dose cohort and the corresponding 95 % 
CI.
The PK/PD modelling procedures were similar to those 
in two recent studies [14, 34]. PK/PD analysis was per-
formed and the minimum parasiticidal concentration 
(MPC) for ferroquine was determined by observational 
and model-based analysis. MPC is the lowest plasma or 
blood concentration of a drug that produces the maxi-
mal anti-malarial effect [2, 35]. The PK/PD modelling 
approach was as outlined previously [36, 37], using Non-
mem VII (Globomax), R (v2.14) and Berkeley Madonna 
(University of California) to model and analyse the 
data. Parameters obtained from the WWARN calcula-




Among 19 subjects screened for Cohort 1, eight sub-
jects were enrolled in the study, infected with P. falcipa-
rum and, upon reaching the predetermined threshold of 
1000 parasites/mL (Additional file 1: Figure S1) received 
treatment with 800  mg ferroquine. Among these sub-
jects, three were males and five females with average age 
26 years (±6.4) and body mass index 23.3 kg/m2 (±1.7). 
Seven were of Caucasian origin, one was Asian. All eight 
subjects completed the study. The initial plan was to 
recruit two cohorts (n = 8 each) for different doses of fer-
roquine. However, the second cohort was not recruited, 
because the key pharmacodynamics parameters were 
successfully obtained in the first cohort, and the Safety 
Review Team recommended not to recruit a second 
cohort after review of safety data (see below).
Pharmacokinetic analysis
The individual plasma exposures to ferroquine and its 
metabolite over time are shown in Fig. 1. Non-compart-
mental analysis was performed on the data to determine 
the PK parameters for the cohort (n = 8), with the results 
presented in Table  1. The observed censored data sup-
ported the fitting of a two-compartment model which 
could be successfully used in both Nonmem® [32] and 
Winnonlin® [39, 40] software packages, with a fit that 
improved when the data were truncated at 264 h. A visual 
predictive check (Additional file  1: Figure S2) demon-
strated that the two-compartment model was sufficient 
for describing PK data until 240 h. A first-order absorp-
tion without a lag phase was the most successful param-
eterization of absorption.
Pharmacodynamic analysis
The reduction in parasitaemia following ferroquine 
treatment as reported by the PRR and parasite clearance 
Time (days afer ferroquine adminstraon)
















































Fig. 1 Time course of individual ferroquine and SSR92713 exposure 
following oral administration of 800 mg ferroquine. Predicted data 
were presented as the 2.5th and 97.5th confidence intervals using 
Berkeley Madonna denoted by the black dashed time courses. The 
model (1000 simulations) used an adjusted first order input
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half-life for the individual participants is shown in Fig. 2 
and Table 2. The overall cohort-specific PRR was 162.9 
(95  % CI 141–188). Two subjects experienced recru-
descence and required A/L treatment at 288 h. For the 
first of these, the parasitaemia nadir for the testing epi-
sode was measured at 132  h (ferroquine dosing was at 
72 h); at this time point, the estimated ferroquine expo-
sure was 22.7 ng/mL (the measured values were 31 and 
17 ng/mL at 96 resp. 144 h). For the second volunteer, 
the nadir was estimated to occur between 150 and 
160  h, with a ferroquine exposure between 16.4 and 
25.2 ng/mL. The cohort parasite clearance half-life was 
6.5 (CI 6.4–6.7) h.
Pharmacokinetic/pharmacodynamic assessments
Based on the clearance rate of 0.09 (0.06–0.10) h−1 esti-
mated from the WWARN calculator [38], we calcu-
lated the time taken for parasitaemia to decrease to an 
extrapolated intercept with either a threshold of 0.003 or 
0.0002  parasites/mL (equivalent to 1 parasite per 70  kg 
subject) and the equivalent concentration of ferroquine 
concurrent with these times. The extrapolation indi-
cated that the duration over which the exposure would 
need to exceed the MPC, on average, had to be greater 
than 142 h (95 % CI 115–211 h). Integration of the MPC 
data and testing within trial simulations indicate a MPC 
of 20 ng/mL (% CV = 20). This analysis predicted that a 
single 800 mg dose of ferroquine would exceed this MPC 
for 454 h (37.8 days) in patients, taking into account that 
clearance is about 32 % lower in patients as compared to 
healthy subjects, thus leading to higher exposure levels in 
patients for a given dose.
Appearance of gametocytes
Results of a PCR-based methodology to investigate 
for presence of the sexual stage of the parasite that is 
transmissible to mosquitoes indicated that all eight sub-
jects became positive for the gametocyte-specific tran-
script pfs25. Transcripts were first detected in the blood 
approximately 7  days after subjects had received ferro-
quine and remained detectable until subjects received a 
dose of primaquine at the end of study (See Additional 
file 1: Figure S3).
Table 1 Non-compartmental analysis parameter estimates 
of the exposure of ferroquine and SSR97213
Ferroquine SSR97213
Cmax (ng/mL)
 Geometric mean 155 89
 Log‑linear CIs (94–257) (49–162)
Tmax (h)
 Median (range) 6 (4–8) 8 (4–12) one subject at 48 h)
C144 h (ng/mL)
 Geometric mean 26 26
 Log‑linear CIs (21–32) (19–36)
Half‑life (h)
 Geometric mean 262 (10.9 days) 661 (27.5 days)
 Range (204–315) (295–1349)
AUC144 h (ng/mL)
 Geometric mean 6893 5525
 Log‑linear CIs (5378–8834) (3883–7861)
AUC0−last (ng/mL)
 Geometric mean 12,406 12,247
 Range (9259–17,826) (6449–19,975)
AUC0−Inf (ng/mL)
 Geometric mean 16,631 31,006
 Range (11,314–25,091) (10,061–55,768)
Time (days after Plasmodium inoculum)





















Fig. 2 Parasitaemia rise and fall following ferroquine treatment for 
the individual participants (red represents the mean)
Table 2. Individual parasite reduction ratios (PRR) 
and half-life (t½) for 800 mg ferroquine
+  Subject R106 had low levels of parasitaemia for a period of time after 144 h 
post treatment. Data for analysis were censored at 144 h
Subject PRR (95 % CI) t½, h (95 % CI)
R101 73 (47–115) 7.75 (7.01–8.66)
R102 140 (99–198) 6.73 (6.29–7.24)
R103 375 (222–634) 5.61 (5.16–6.16)
R104 244 (129–460) 6.05 (5.43–6.84)
R105 250 (116–542) 6.02 (5.29–7.00)
R106+ 78 (60–101) 7.64 (7.21–8.13)
R107 124 (69–220) 6.91 (6.17–7.85)
R108 479 (356–646) 5.39 (5.14–5.66)
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Safety
Of the total of 84 adverse events reported (see Additional 
file  1: Table S1), 12 were assessed as possibly related to 
the inoculum (i.e. malaria-related), 42 were assessed 
as probably related to the inoculum, and seven were 
assessed as unlikely to be related, or unrelated to inocu-
lation (see Additional file 1: Table S1). Of those adverse 
events possibly or probably related to malaria, 40 events 
occurred after the administration of ferroquine and 
before commencement of A/L, and two within 1  day of 
the start of A/L. Eight adverse events were assessed as 
probably, and three events were considered to be pos-
sibly related to ferroquine (nausea and transient eleva-
tion of transaminase levels). This study was put on hold 
following the occurrence of these three separate events 
occurring in three subjects that were classified as seri-
ous adverse events (SAEs) by the sponsor. As discussed 
above, this formed part of the rationale not to undertake 
a second cohort.
Eight days after inoculation, prior to ferroquine admin-
istration, a single subject had clinically significant ele-
vated transaminases of AST 110  U/L and ALT 81  U/L 
(reference range 10–40 and 5–40 U/L for AST and ALT 
respectively) that was identified on a per protocol bio-
chemical test. Transient derangements of liver function 
tests (LFTs) of this magnitude are routinely observed in 
IBSM studies. These changes normalized post confine-
ment for ferroquine treatment, but increased again after 
end of study treatment with A/L, peaking at levels of AST 
208 U/L and ALT 347 U/L on day 28 (day 20 post ferro-
quine). The relationship of these derangements with the 
administration of ferroquine could not be determined 
with certainty, as the ALT peak occurred after the sub-
ject had received A/L treatment, which can lead to tran-
sient elevation of transaminases [41]. These changes had 
returned to baseline by day 42. A second subject was 
found to have significant elevations in transaminase lev-
els (AST 355 U/L and ALT 247 U/L) 3 days after receiving 
ferroquine (day 11). These peaked on day 12 at 693 and 
536 U/L for AST and ALT respectively before returning 
to near normal ranges by days 21 and 28 and remained 
normal to day 44. A third subject was also noted to have 
clinically significant elevation of transaminase levels of 
AST 252  U/L and ALT 396  U/L 5  days after ferroquine 
administration (day 13). These parameters returned to 
near-normal by day 16, but the ALT rose again follow-
ing A/L treatment to reach a level of 144 U/L on day 19. 
At the end of study (day 28), the subject’s biochemistry 
test was within the normal range. Note that volunteers 
were confined only for 48  h, therefore, non-ferroquine-
related factors may have contributed to ALT/AST eleva-
tions. As bilirubin levels remained normal at all times, 
these derangements in liver function were not considered 
SAEs according to Hy’s Law [42]. Paracetamol was the 
only concomitant treatment among subjects that may 
have played a role in the elevated ALT/AST levels, as 
these were observed in two out of the three subjects in 
this study who required paracetamol for symptom relief 
of headaches/fever. In addition abnormal haematology 
results (neutropenia and/or thrombocytopenia) were 
reported in these two subjects, preceding the transami-
nitis event onset, which were attributed to the onset of 
malaria).
In the absence of the identification of another plausible 
cause, and with the temporal association following ferro-
quine administration it was concluded that these adverse 
events were likely attributable to ferroquine. However, 
given the concurrence of a range of other potential 
hepatic irritants (notably malaria, and concurrent medi-
cations), it not possible to exclude these as cofactors. No 
clinically significant ECG abnormalities were observed.
Discussion
The PRR calculated for ferroquine in this study (163; 
95  % CI 141–188) corresponds to the 10–103 range 
reported earlier for quinine, mefloquine and sulfadox-
ine-pyrimethamine, and thus is somewhat in the lower 
range of 102–104 for 4-aminoquinolines and halofantrine, 
and 103–105 for artemisinins [43]. The present study is 
expected to be typical for malaria-naïve individuals who 
would be more susceptible to clinical illness, and fur-
ther not have clearance estimates elevated by immunity, 
compared to patients in malaria-endemic areas [44]. PRR 
variation due to differences between patient and volun-
teer status was recently highlighted [45]. As reported 
elsewhere [16], it would therefore seem that the principal 
benefit of the added ferrocene moiety in ferroquine, com-
pared to its predecessor chloroquine, is its activity against 
chloroquine-resistant parasites, with a good overall fit to 
Target Compound Profile 1 as described earlier [2, 46]. 
In this respect it is important to note that the P. falcipa-
rum strain tested, 3D7, is chloroquine-sensitive. Possible 
future use of the chloroquine-resistant challenge strain 
7G8 [47] may offer a means of addressing the activity of 
ferroquine against chloroquine-resistant parasites. The 
study described here also confirms ferroquine’s attractive 
in vivo half-life (11 days), which suggests that it may be a 
suitable partner drug when paired with short half-life and 
fast-acting drugs including artemisinins and related per-
oxides, and thereby fit to Target Compound Profile 2 [2]. 
As the rate of parasite killing is believed to be constant 
while the drug concentration remains above the MPC, 
the parasite clearance half-life and PRR can be derived 
during the initial phase of parasite killing. The parasi-
taemia levels in volunteers in this experimental infection 
system are orders of magnitude lower than those seen in 
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patients and it is, therefore, possible that PD effects may 
be affected by parasite concentration. However, PD data 
from two recently published studies of mefloquine [14]) 
and OZ439 [34] in the IBSM model were close to those 
reported in studies undertaken in patients with clinical 
malaria [48, 49].
The appearance of gametocytes after anti-malarial 
treatment is an observation previously made, both in 
field studies [50] and in IBSM studies [33] and [51]. The 
fact that the signal persisted in the presence of both fer-
roquine and its active metabolite suggests that at least 
mature female gametocytes are not cleared in  vivo by 
ferroquine. Without mosquito transmission data it is 
not possible to determine if ferroquine-treated sub-
jects would be infectious to mosquitoes. Factors that 
may influence this include the (unmeasured) activity of 
the drug against male gametocytes and possible dam-
age to the parasites that may prevent sporogony in the 
mosquito.
While ferroquine was, overall, well tolerated, three 
subjects experienced increased transaminase read-
ings. Although transient Grade 1 (WHO) elevations 
of transaminase are typically observed in IBSM stud-
ies, these typically occur at earlier timepoints than was 
observed in two of the three subjects reported here. In 
two of the three subjects transaminases peaked 3–5 days 
after ferroquine administration (at 693 and 536 U/L and 
252 and 396  U/L for AST and ALT respectively) before 
returning to normal values. Intensive investigation, 
including a measurement of paracetamol levels did not 
reveal a definitive cause for these changes. Increased 
transaminase readings had also been seen in four adult 
patients in the recent ferroquine Phase II trial, which 
involved 187 patients, again in absence of concomitant 
abnormal bilirubin readings [29]. That study, too, permit-
ted the use of paracetamol, along with contraceptives, 
as the only permissible concomitant treatment. Toxic 
paracetamol (over-)dosing is well known to cause acute 
liver toxicity but even normal use may result in modestly 
increased AST and ALT readings in the absence of ele-
vated bilirubin levels [51–54]. Further establishment of 
ferroquine’s safety profile will require additional clinical 
trials.
Conclusions
In conclusion, ferroquine showed adequate anti-parasitic 
efficacy with clearance of parasitaemia in all eight sub-
jects treated. The parameters derived from the PK/PD 
model of ferroquine, combined with its long in vivo half-
life, indicate that ferroquine has potential in the devel-
opment of new combination anti-malarial treatments. 
However, additional clinical trials are needed to evalu-
ate the safety of ferroquine beyond the small number of 
participants in this study. Subjects should undergo care-
ful liver function monitoring while taking this investiga-
tional drug. This study provides important information 
about the efficacy and tolerability of ferroquine, which 
would be beneficial for further development of the drug 
as a partner in a combination treatment.
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